You Position: Home > Paper

Clinical efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy after cytoreductive surgery for ovarian carcinoma: a meta-analysis

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Journal of Biomedical Engineering
Issue:
5
DOI:
10.3760/cma.j.issn.1674-1927.2011.05.019
Key Word:
卵巢肿瘤;治疗结果;Meta分析;细胞减瘤术;腹腔热灌注化疗;Ovarian neoplasms;Treatment outcome;Meta-analysis;Cytoreductive surgery;Hyperthermic intraperitoneal perfusion chemotherapy

Abstract´╝Ü Objective To analyze the clinical efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy (HIPC) after cytoreductive surgery for ovarian carcinoma.Methods Based on the pre-designed criteria,the articles published were searched and recorded for data on types and options of surgery,use of HIPC,complications,mortalities,hospital stays and survival time.The dosage of chemotherapy agents,method of hyperthermic perfusion and duration of chemotherapy were also described.Results Fourteen articles were finally included in this meta-analysis.Among these,7 studies showed favorable patient outcomes with HIPC after radical tumor resection.The median survival time and median disease-free survival for primary ovarian carcinoma and relapsed ovarian carcinoma ranged from 22 to 54months and 10 to 26 months,respectively.The incidence of serious complications with HIPC after cytoreductive surgery ranged from 5% to 36%,with the median mortality being 3% (0% -10% ).The incidence of complications and the mortality were low.Conclusion HIPC after cytoreductive surgery may be used as a promising treatment which is clinically safe and feasible.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn